

# Resource Summary Report

Generated by [dkNET](#) on Aug 20, 2026

## Recombinant Anti-Bak antibody [Y164] - BSA and Azide free

RRID:AB\_3073771

Type: Antibody

---

### Proper Citation

Abcam Cat# ab220790, RRID:AB\_3073771

---

### Antibody Information

**URL:** [http://antibodyregistry.org/AB\\_3073771](http://antibodyregistry.org/AB_3073771)

**Proper Citation:** Abcam Cat# ab220790, RRID:AB\_3073771

**Target Antigen:** BAK

**Host Organism:** Rabbit

**Clonality:** recombinant monoclonal

**Comments:** Applications: Flow Cyt (Intra), WB, IHC-P, IP

**Antibody Name:** Recombinant Anti-Bak antibody [Y164] - BSA and Azide free

**Description:** This recombinant monoclonal targets BAK

**Target Organism:** human

**Clone ID:** Y164

**Antibody ID:** AB\_3073771

**Vendor:** Abcam

**Catalog Number:** ab220790

**Record Creation Time:** 20250820T012402+0000

**Record Last Update:** 20250820T104950+0000

---

### Ratings and Alerts

No rating or validation information has been found for Recombinant Anti-Bak antibody [Y164] - BSA and Azide free.

No alerts have been found for Recombinant Anti-Bak antibody [Y164] - BSA and Azide free.

---

## Data and Source Information

**Source:** [Antibody Registry](#)

---

## Usage and Citation Metrics

We found 1 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [dkNET](#) .

Lakhani NJ, et al. (2024) First-in-Human Study with Preclinical Data of BCL-2/BCL-xL Inhibitor Pelcitoclax in Locally Advanced or Metastatic Solid Tumors. Clinical cancer research : an official journal of the American Association for Cancer Research, 30(3), 506.